Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Protocol for a Multicenter, Double-Blind, Randomized, Placebo Controlled, Comparison of the Efficacy and Safety of Bextra® (Valdecoxib) 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe RA Population

NCT00650455 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00650455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00650455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Protocol for a Multicenter, Double-Blind, Randomized, Placebo Controlled, Comparison of the Efficacy and Safety of Bextra® (Valdecoxib) 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe RA Population
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2003
Completion date
January 31, 2005
Enrollment
489 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid